Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Jetstar to Charge for Overhead Cabin Bags From February 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
MENLO PARK, Calif., March 21, 2018 -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Time on Tuesday, March 27, 2018.
A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/needham86/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
